Dr. Nishi Suryavanshi Receives Award from ACTG Network

Date: 01/07/2022

Congratulations, Nishi Suryavanshi, recipient of ACTG’s Tuberculosis Transformative Science Group Special Contributions Award.

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...